{
    "nctId": "NCT04288089",
    "briefTitle": "A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer",
    "officialTitle": "An Open-Label Multicenter Phase 1b Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive HER2-Negative Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Receptors, Estrogen, Genes, Erbb-2, Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 31,
    "primaryOutcomeMeasure": "Maximum Tolerated Dose (MTD) of H3B-6545 and Palbociclib",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. ER+ HER2- locally advanced, recurrent, or metastatic breast cancer, as per local laboratory\n2. Prior therapy in the advanced/metastatic setting\n3. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n4. Has adequate bone marrow and organ function\n\nExclusion Criteria:\n\n1. Uncontrolled significant active infections\n2. Major surgery or other locoregional treatment within 4 weeks before the 1st dose of study drug\n3. Inability to take oral medication or presence of malabsorption\n4. Active cardiac disease or a history of cardiac dysfunction\n5. Evidence of ongoing Alcohol or Drug Abuse",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}